Corpus ID: 9103791

Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.

  title={Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.},
  author={Guido Tricot and George Weber},
  journal={Anticancer research},
  volume={16 6A},
Conventional antileukemic chemotherapy in relapsed or refractory acute leukemia or myeloid blast crisis of chronic granulocytic leukemia (CGL) is not curative and remissions, if attained, are usually of short duration. The primary goal of antileukemic therapy in these patients should be the identification of agents that are more selective and better targeted in their action. Tiazofurin is known to inhibit inosine 5'-phosphate dehydrogenase (IMPDH), the rate limiting enzyme of de novo guanine… Expand
In vitro sensitivity of hematopoietic progenitors to tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia.
It has been demonstrated that TR has strong in vitro anti-leukemic activity, more pronounced in bcCML than in refractory AML, and further rationale for the clinical application of TR is given. Expand
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Findings indicate that the efficacy of standard chemotherapy in bcr-abl positive leukemias might be enhanced if combined sequentially with Tiazofurin. Expand
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
It is demonstrated that mycophenolic acid (MPA), a specific inosine monophosphate dehydrogenase (IMPDH) inhibitor that results in depletion of intracellular guanine nucleotides, is synergistic with imatinib in inducing apoptosis in Bcr-Abl-expressing cell lines. Expand
Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines
Results suggest that in neuroblastoma cell lines clinically attainable concentrations of mycophenolic acid deplete guanine nucleotide pools triggering G1 arrest and apoptosis through p53‐mediated pathways, indicating a potential role of its morpholinoethyl ester pro‐drug in the management of patients with neuroectodermal tumors. Expand
Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
It is concluded that resveratrol could become a viable candidate as one compound in the combination chemotherapy of leukemia and therefore deserves further testing. Expand
Promising Approaches in Acute Leukemia
Some of the promising approaches currently being investigated in the treatment of acute leukemias offer the promise of finding a cure for the majority of patients with leukemia in the near future. Expand
Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation.
Ribavirin is a potent anticancer agent, being a strong inducer of apoptosis and a moderate inducers of differentiation in K562 cells, mediated through the modulation of key molecular and metabolic pathways. Expand
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story
The history of IMPDH inhibitors, the development of new inhibitors as anti-cancer drugs, and future directions and strategies to overcome existing challenges are summarized. Expand
The synergistic apoptotic effects of thiophenfurin, an inosine monophosphate dehydrogenase inhibitor, in combination with retinoids in HL60 cells.
The results show that thiophenfurin is capable of eliciting significant S phase-specific antiproliferative effects in different sensitive and resistant cell lines with the IC50s, suggesting the possible usefulness of this combination in the treatment of leukaemia. Expand
From ribavirin to NAD analogues and back to ribavirin in search for anticancer agents
Abstract Ribavirin, a broad-spectrum antiviral agent is used in the clinic alone or in combination with other antivirals and/or interferons. Numerous structural analogues of ribavirin have beenExpand